ASH 2024: IVIG Use With Bispecific Antibodies

Linvoseltamab represents a promising new approach to treating multiple myeloma through immune-based therapy.

In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

During a live event, Jeffrey V. Matous, MD, discussed flexible dosing and the need to expand use in community practices for teclistamab in myeloma.

In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

During a live event, Alfred L. Garfall, MD, discussed the dose adjustments and supportive care for toxicities seen with talquetamab in multiple myeloma.

During a live event, Taewoong Choi, MD, discussed the potential use of quadruplet in transplant-ineligible multiple myeloma and the need for monitoring for neuropathy with bortezomib.